Renowned Pathologist Dr. Meryl H. Haber Joins E Med Future as Advisor

COLUMBUS, Ohio -- E Med Future, Inc., manufacturer of NeedleZap, a medical device that disintegrates used hypodermic needles, announced today that Meryl H. Haber, M.D. has agreed to work with the company as an advisor effective immediately, and is expected to be nominated to the board of directors at the next annual shareholders meeting.

"As an internationally recognized leader in the field of pathology with more than 40 years of medical expertise, Dr. Haber is a welcome addition to E Med Future," said Robert J. Ochsendorf, president. "We're delighted to have his involvement in the development and marketing of NeedleZap, and future product line extensions."

Haber was the Borland Professor and Chairman of the Department of Pathology at Rush-Presbyterian-St. Luke's Medical Center in Chicago until 2000, and currently serves as an Emeritus Professor of Pathology at Rush Medical College. Other academic appointments for Dr. Haber have included Northwestern University Medical School, University of Hawaii School of Medicine, and the University of Nevada, School of Medical Sciences.

Over the years, Haber has held key positions in various professional organizations including the American Society of Clinical Pathologists, College of American Pathologists and the Society for Academic Continuing Medical Education. His articles have appeared in more than 50 publications and he has written or co-authored more than a dozen textbooks or chapters on a variety of medical-related topics.

"As a physician and pathologist, I am particularly interested in NeedleZap and its immense possibilities for use in the health sciences, where issues of safety are of the utmost importance," said Haber.

E Med manufactures a new portable needle destruction device, NeedleZap, developed specifically to help reduce accidental needlestick injuries in the workplace. When a used hypodermic needle is inserted into the unit, the patented electrode system disintegrates the needle in approximately two seconds at 2200 degrees F, leaving the syringe intact. With the recent approval order from the FDA, E Med can market NeedleZap to a wide-ranging audience base that includes physicians, hospitals/clinics, home healthcare providers, long term care facilities, dental care professionals, veterinary facilities, law enforcement professionals, hospitality venues, the military and homeland security personnel. The company currently has worldwide distribution agreements with American Health & Safety Products, Inc., and their wholly owned subsidiary AHSP International L.L.C.

Source: E Med Future, Inc.